Company intelligence / Profile preview

Quadira Biosciences

Solothurn, Solothurn, Switzerlandquadirabiosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Quadira Biosciences has developed a lead ADC candidate, QBK249-G, targeting HER2-positive breast cancer. Preclinical data show an eightfold higher antitumor efficacy compared to currently marketed ADCs at a tenfold lower concentration with comparable toxicity, indicating improved biotolerability. The company claims rapid development timelines for new ADCs using its combined technology platforms and is preparing licensing documents for its first product.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Partnerships

Veraxa Biotech GmbHabc biopply AGXlife Sciences AGAnfass Life Technologies AG

Beyond the preview

Go deeper on Quadira Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quadira Biosciences.

Explore the full profile